Abstract
Nanotechnology is a field which has been at the forefront of research over the past two decades. The full potential of nanotechnology has yet to be fully realized. One subset of nanotechnology that has emerged is nanomedicine, which has been able to exploit the unique properties of nano-sized particles for therapeutics. Nanomedicine has the potential to increase the specific treatment of cancer cells while leaving healthy cells intact through the use of novel nanoparticles to seek and treat cancer in the human body. However, there are undoubtedly toxicities, which have not yet been fully elucidated. Various nano-carriers such as nanoshells, nanocrystals, nanopolymers, quantum dots, and dendrimers, and their role in early cancer detection and treatment have been discussed in this article.
Similar content being viewed by others
References
Garcia, M., Jemal, A., Ward, E. M., Center, M. M., Hao, Y., Siegel, R. L., et al. (2007). Global cancer facts & figures. Atlanta, GA, USA: The American Cancer Society.
Cancer to be world’s top killer by 2010, World Health Organization says’. (2009). http://www.mlive.com/news/kalamazoo/index.ssf/2008/12/cancer_to_be_worlds_top_killer.html. Accessed 9 Dec 2008.
Jain, R. K. (2005). Antiangiogenic therapy for cancer: Current and emerging concepts. Oncology, 19, 7–16. Williston Park.
Maeda, H., Fang, J., Inutsuka, T., & Kitamoto, Y. (2003). Vascular permeability enhancement in solid tumor: Various factors, mechanisms involved and its implications. International Immunopharmacology, 3, 319–328. doi:10.1016/S1567-5769(02)00271-0.
Netti, P. A., Baxter, L. T., Boucher, Y., Skalak, R., & Jain, R. K. (1995). Time-dependent behavior of interstitial fluid pressure in solid tumors: Implications for drug delivery. Cancer Research, 55, 5451–5458.
Matsumura, Y., & Maeda, H. (1986). A new concept for macromolecular therapeutics in cancer chemotherapy: Mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Research, 46, 6387–6392.
Iyer, A. K., Khaled, G., Fang, J., & Maeda, H. (2006). Exploiting the enhanced permeability and retention effect for tumor targeting. Drug Discovery Today, 11, 812–818. doi:10.1016/j.drudis.2006.07.005.
Maeda, H., Wu, J., Sawa, T., Matsumura, Y., & Hori, K. (2000). Tumor vascular permeability and the EPR effect in macromolecular therapeutics: A review. Journal of Controlled Release, 65, 271–284. doi:10.1016/S0168-3659(99)00248-5.
Ferrari, M. (2005). Cancer nanotechnology: Opportunities and challenges. Nature reviews. Cancer, 5, 161–171. doi:10.1038/nrc1566.
Cuenca, A. G., Jiang, H., Hochwald, S. N., Delano, M., Cance, W. G., & Grobmyer, S. R. (2006). Emerging implications of nanotechnology on cancer diagnostics and therapeutics. Cancer, 107, 459–466. doi:10.1002/cncr.22035.
Smith, A. M., Dave, S., Nie, S., True, L., & Gao, X. (2006). Multicolor quantum dots for molecular diagnostics of cancer. Expert Review of Molecular Diagnostics, 6, 231–244. doi:10.1586/14737159.6.2.231.
Stroh, M., Zimmer, J. P., Duda, D. G., Levchenko, T. S., Cohen, K. S., Brown, E. B., et al. (2005). Quantum dots spectrally distinguish multiple species within the tumor milieu in vivo. Nature Medicine, 11, 678–682. doi:10.1038/nm1247.
Lidke, D. S., Nagy, P., Heintzmann, R., Arndt-Jovin, D. J., Post, J. N., Grecco, H. E., et al. (2004). Quantum dot ligands provide new insights into erbB/HER receptor-mediated signal transduction. Nature Biotechnology, 22, 198–203. doi:10.1038/nbt929.
Medintz, I. L., Uyeda, H. T., Goldman, E. R., & Mattoussi, H. (2005). Quantum dot bioconjugates for imaging, labelling and sensing. Nature Materials, 4, 435–446. doi:10.1038/nmat1390.
Wu, X., Liu, H., Liu, J., Haley, K. N., Treadway, J. A., Larson, J. P., et al. (2003). Immunofluorescent labeling of cancer marker Her2 and other cellular targets with semiconductor quantum dots. Nature Biotechnology, 21, 41–46. doi:10.1038/nbt764.
Akerman, M. E., Chan, W. C., Laakkonen, P., Bhatia, S. N., & Ruoslahti, E. (2002). Nanocrystal targeting in vivo. Proceedings of the National Academy of Sciences of the United States of America, 99, 12617–12621. doi:10.1073/pnas.152463399.
Liu, Y., Steiniger, S. C., Kim, Y., Kaufmann, G. F., Felding-Habermann, B., & Janda, K. D. (2007). Mechanistic studies of a peptidic GRP78 ligand for cancer cell-specific drug delivery. Molecular Pharmaceutics, 4, 435–447. doi:10.1021/mp060122j.
Gao, C., Mao, S., Ditzel, H. J., Farnaes, L., Wirsching, P., Lerner, R. A., et al. (2002). A cell-penetrating peptide from a novel pVII-pIX phage-displayed random peptide library. Bioorganic & Medicinal Chemistry, 10, 4057–4065. doi:10.1016/S0968-0896(02)00340-1.
Loo, C., Lin, A., Hirsch, L., Lee, M. H., Barton, J., Halas, N., et al. (2004). Nanoshell-enabled photonics-based imaging and therapy of cancer. Technology in Cancer Research & Treatment, 3, 33–40.
Sokolov, K., Follen, M., Aaron, J., Pavlova, I., Malpica, A., Lotan, R., et al. (2003). Real-time vital optical imaging of precancer using anti-epidermal growth factor receptor antibodies conjugated to gold nanoparticles. Cancer Research, 63, 1999–2004.
Yezhelyev, M. V., Gao, X., Xing, Y., Al-Hajj, A., Nie, S., & O’Regan, R. M. (2006). Emerging use of nanoparticles in diagnosis and treatment of breast cancer. The lancet Oncology, 7, 657–667. doi:10.1016/S1470-2045(06)70793-8.
Shen, T., Weissleder, R., Papisov, M., Bogdanov, A., Jr, & Brady, T. J. (1993). Monocrystalline iron oxide nanocompounds (MION): Physicochemical properties. Magnetic Resonance in Medicine, 29, 599–604. doi:10.1002/mrm.1910290504.
Harisinghani, M. G., Barentsz, J., Hahn, P. F., Deserno, W. M., Tabatabaei, S., Van de Kaa, C. H., et al. (2003). Noninvasive detection of clinically occult lymph-node metastases in prostate cancer. The New England Journal of Medicine, 348, 2419–2491. doi:10.1056/NEJMoa022749.
Messing, E. M., Manola, J., Sarosdy, M., Wilding, G., Crawford, E. D., & Trump, D. (1999). Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer. The New England Journal of Medicine, 341, 1781–1788. doi:10.1056/NEJM199912093412401.
Fritz, J., Baller, M. K., Lang, H. P., Rothuizen, H., Vettiger, P., Meyer, E., et al. (2000). Translating biomolecular recognition into nanomechanics. Science, 288, 316–318. doi:10.1126/science.288.5464.316.
Wu, G., Datar, R. H., Hansen, K. M., Thundat, T., Cote, R. J., & Majumdar, A. (2001). Bioassay of prostate-specific antigen (PSA) using microcantilevers. Nature Biotechnology, 19, 856–860. doi:10.1038/nbt0901-856.
Sengupta, S., & Sasisekharan, R. (2007). Exploiting nanotechnology to target cancer. British Journal of Cancer, 96, 1315–1319.
Yue, M., Stachowiak, J. C., & Majumdar, A. (2004). Cantilever arrays for multiplexed mechanical analysis of biomolecular reactions. Mechanics & Chemistry of Biosystems; MCB, 1, 211–220.
Kwon, G. S. (2003). Polymeric micelles for delivery of poorly water-soluble compounds. Critical Reviews in Therapeutic Drug Carrier Systems, 20, 357–403. doi:10.1615/CritRevTherDrugCarrierSyst.v20.i5.20.
Sparreboom, A., Scripture, C. D., Trieu, V., Williams, P. J., De, T., Yang, A., et al. (2005). Comparative preclinical and clinical pharmacokinetics of a cremophor-free, nanoparticle albumin-bound paclitaxel (ABI-007) and paclitaxel formulated in Cremophor (Taxol). Clinical Cancer Research, 11, 4136–4143. doi:10.1158/1078-0432.CCR-04-2291.
Gradishar, W. J., Tjulandin, S., Davidson, N., Shaw, H., Desai, N., Bhar, P., et al. (2005). Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. Journal of Clinical Oncology, 23, 7794–7803. doi:10.1200/JCO.2005.04.937.
Moreno-Aspitia, A., & Perez, E. A. (2005). Nanoparticle albumin-bound paclitaxel (ABI-007): A newer taxane alternative in breast cancer. Future Oncology (London, England), 1, 755–762. doi:10.2217/14796694.1.6.755.
Martin, F. J. (1998). Clinical pharmacology and antitumor efficacy of DOXIL (pegylated liposomal doxorubicin): Medical applications of liposomes. In D. D. Lasic & D. Papahadjopoulos (Eds.) (pp. 635–688). New York, NY: Elsevier Science BV.
Nishiyama, N. & Kataoka, K. (2006). Current state, achievements, and future prospects of polymeric micelles as nanocarriers for drug and gene delivery. Pharmacol Theory, 112, 630–648.
Park, J. W. (2002). Liposome-based drug delivery in breast cancer treatment. Breast Cancer Research, 4, 95–99. doi:10.1186/bcr432.
Gao, X., Yang, L., Petros, J. A., Marshall, F. F., Simons, J. W., & Nie, S. (2005). In vivo molecular and cellular imaging with quantum dots. Current Opinion in Biotechnology, 16, 63–72. doi:10.1016/j.copbio.2004.11.003.
Farokhzad, O. C., Cheng, J., Teply, B. A., Sherifi, I., Jon, S., Kantoff, P. W., et al. (2006). Targeted nanoparticle-aptamer bioconjugates for cancer chemotherapy in vivo. Proceedings of the National Academy of Sciences of the United States of America, 103, 6315–6320. doi:10.1073/pnas.0601755103.
Hirsch, L. R., Stafford, R. J., Bankson, J. A., Sershen, S. R., Rivera, B., Price, R. E., et al. (2003). Nanoshell-mediated near-infrared thermal therapy of tumors under magnetic resonance guidance. Proceedings of the National Academy of Sciences of the United States of America, 100, 13549–13554. doi:10.1073/pnas.2232479100.
El-Sayed, I. H., Huang, X., & El-Sayed, M. A. (2006). Selective laser photo-thermal therapy of epithelial carcinoma using anti-EGFR antibody conjugated gold nanoparticles. Cancer Letters, 239, 129–135. doi:10.1016/j.canlet.2005.07.035.
Loo, C., Lowery, A., Halas, N., West, J., & Drezek, R. (2005). Immunotargeted nanoshells for integrated cancer imaging and therapy. Nano Letters, 5, 709–711. doi:10.1021/nl050127s.
Sengupta, S., Eavarone, D., Capila, I., Zhao, G., Watson, N., Kiziltepe, T., et al. (2005). Temporal targeting of tumour cells and neovasculature with a nanoscale delivery system. Nature, 436, 568–572. doi:10.1038/nature03794.
Jain, R. K. (2001). Normalizing tumor vasculature with anti-angiogenic therapy: A new paradigm for combination therapy. Nature Medicine, 7, 987–989. doi:10.1038/nm0901-987.
Yacoby, I., Bar, H., & Benhar, I. (2007). Targeted drug-carrying bacteriophages as antibacterial nanomedicines. Antimicrobial Agents and Chemotherapy, 51, 2156–2163. doi:10.1128/AAC.00163-07.
Bar, H., Yacoby, I., & Benhar, I. (2008). Killing cancer cells by targeted drug-carrying phage nanomedicines. BMC Biotechnology, 8, 37. doi:10.1186/1472-6750-8-37.
Kojima, C., Kono, K., Maruyama, K., & Takagishi, T. (2000). Synthesis of polyamidoamine dendrimers having poly(ethylene glycol) grafts and their ability to encapsulate anticancer drugs. Bioconjugate Chemistry, 11, 910–917. doi:10.1021/bc0000583.
Pathak, P. (2007). Multi-functional nanoparticles and their role in cancer drug delivery––a review. Journal of Nanotechnology Online, 3, 1–17.
Li, Y., Cheng, Y., & Xu, T. (2007). Design, synthesis and potent pharmaceutical applications of glycodendrimers: A mini review. Current Drug Discovery Technologies, 4, 246–254. doi:10.2174/157016307783220503.
Cheng, Y., Wang, J., Rao, T., He, X., & Xu, T. (2008). Pharmaceutical applications of dendrimers: Promising nanocarriers for drug delivery. Frontiers in Bioscience, 13, 1447–1471. doi:10.2741/2774.
Bawarski, W. E., Chidlowsky, E., Bharali, D. J., & Mousa, S. A. (2008). Emerging nanopharmaceuticals. Nanomedicine, 4, 273–282.
De Jong, W. H., & And Borm, P. J. (2008). Drug delivery and nanoparticles: Applications and hazards. International Journal of Nanomedicine, 3, 133–149.
Moghimi, S. M., Hunter, A. C., & Murray, J. C. (2005). Nanomedicine: Current status and future prospects. The FASEB Journal, 19, 311–330. doi:10.1096/fj.04-2747rev.
Derfus, A. M., Chan, W. C., & Bhatia, S. N. (2004). Probing the cytotoxicity of semiconductor quantum dots. Nano Letters, 4, 11–18. doi:10.1021/nl0347334.
Mecke, A., Uppuluri, S., Sassanella, T. M., Lee, D. K., Ramamoorthy, A., Baker, J. R., Jr, et al. (2004). Direct observation of lipid bilayer disruption by poly(amidoamine) dendrimers. Chemistry and Physics of Lipids, 132, 3–14. doi:10.1016/j.chemphyslip.2004.09.001.
Gettinger, S. (2008). Targeted therapy in advanced non-small-cell lung cancer. Seminars in Respiratory and Critical Care Medicine, 29(3), 291–301. doi:10.1055/s-2008-1076749.
Patel, D. K. (2008). Clinical use of anti-epidermal growth factor receptor monoclonal antibodies in metastatic colorectal cancer. Pharmacotherapy, 28(11 pt 2), 31S–41S. doi:10.1592/phco.28.11-supp.31S.
Dean-Colomb, W., & Esteva, F. J. (2008). Her2-positive breast cancer: Herceptin and beyond. European Journal of Cancer, 44(18), 2806–2812. doi:10.1016/j.ejca.2008.09.013.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
LaRocque, J., Bharali, D.J. & Mousa, S.A. Cancer Detection and Treatment: The Role of Nanomedicines. Mol Biotechnol 42, 358–366 (2009). https://doi.org/10.1007/s12033-009-9161-0
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12033-009-9161-0